Table of Contents

Foreword .................................................................................................................. V
Foreword ................................................................................................................... VII
Introduction ............................................................................................................... IX

Part I  Contrast Agent Properties and Technical Aspects

1  MRI Contrast Media – Introduction and Basic Properties of the Blood Pool Agent Vasovist® ........................................ 3
   Martin Rohrer

2  Contrast Enhanced MRA – First Pass and Steady State .................................. 17
   Harald H. Quick

Part II  Safety and Efficacy

3  Risks and Safety Issues Related to Radiological Imaging, in Particular MRI. .......... 35
   Gunnar Brix

4  Summary of Safety of Vasovist® at 0.03 mmol/kg Body Weight Dose – Clinical Data .................................................. 43
   Matthias Voth and Andrea Löwe

5  Efficacy of Vasovist®: Overview of the Clinical Development Program ............... 51
   Mathias Goyen

Part III  Blood Pool Agents in MRA: Indications, Clinical Applications and Benefits

6  Head and Neck MRA ......................................................................................... 59
   Marco Essig

7  Pulmonary MRA ................................................................................................. 69
   Christian Fink, Ulrike Attenberger, and Konstantin Nikolaou

8  Abdominal MRA ............................................................................................... 81
   Henrik Michaely

9  MRA of the Peripheral Vasculature ................................................................. 93
   Tim Leiner and Jeffrey H. Maki

10 Magnetic Resonance Venography ....................................................................... 115
    Giles Roditi
11 Whole-body MRA .................................................. 131
Harald Kramer, Maximilian E. Reiser, and Konstantin Nikolaou

12 Endoleak Imaging .................................................. 139
Sandra A.P. Cornelissen, Mathias Prokop, Hence J.M. Verhagen, and Lambertus W. Bartels

13 Gastrointestinal Bleeding ........................................... 147
Joachim Lotz

Part IV  New Horizons in Vascular Diagnostics

14 Vasovist® for Ischemic and Congenital Heart Disease .................................. 159
Sebastian Kelle, Gerald Greil, Reza Razavi, and Eike Nagel

15 Vasovist® in Brain Tumor Imaging .................................. 169
Marco Essig and Clemens Fitzek

16 Vasovist® in Lymph Node Imaging: Present Status and Future Development ....... 181
Max J. Lahaye, R. Bert Jan de Bondt, Sanne M.E. Engelen, Geerard L. Beets,
and Regina G.H. Beets-Tan

17 Vasovist® for Breast Cancer Recognition .................................. 193
Joan C. Vilanova and Klaus Wasser

18 Vasovist® for Multiple Sclerosis Recognition .................................. 199
Michael Forsting

19 Vasovist® in Interventional MR Imaging .................................. 207
Michael Bock and Frank Wacker

20 Vasovist® in Lymphography ........................................... 219
Christoph U. Herborn

Part V  Image Processing

21 Image Post-processing of Blood Pool MR Angiograms .................................. 227
Joachim Graessner

Part VI  Pharmacoeconomic Impact

22 Health Economic Assessment of Vasovist® – Technical, Clinical
and Cost Benefits .................................................. 241
Carsten Schwenke, Susanne Kienbaum, and Karsten Bergmann

23 Patient Management and Referrals: Impact of High-Resolution Steady State
MRA with Vasovist® ........................................... 251
Winfried A. Willinek and Dariusch R. Hadizadeh
MRI Contrast Media – Introduction and Basic Properties of the Blood Pool Agent Gadofosveset (Vasovist®)

Martin Rohrer

1.1 Introduction – 4
1.1.1 Basic Mode of Action of MRI Contrast Media – 4
1.1.2 Metal Complexes (Gd-Chelates) – 4
1.1.3 Iron Oxide Nanoparticles – 5
1.1.4 Overview of Currently Marketed MRI Contrast Media – 5

1.2 Blood Pool Contrast Media for MRI – 5
1.2.1 Cellular Target Component: Erythrocyte-bound or Liposomal Systems – 6
1.2.2 Aqueous Target Component: Macromolecules – Polymers, Iron-oxide Particles and Covalently Bound Metal Complexes – 6
1.2.3 Proteins as Target Component: Non-covalently Bound Metal Complexes – 6

1.3 Molecular Structure and Physicochemical Properties – 6

1.4 Biophysical Properties – Reversible Protein Binding – 8
1.4.1 Pharmacokinetics – Prolonged Retention Time – 8
1.4.2 Pharmacodynamics – Relaxivity – 10
1.4.3 Causes for Increased Relaxivity Due to Protein Binding – 11

1.5 Implications for Clinical Application – 12
1.5.1 Relevant Implications for Application in the First Pass – 12
1.5.2 Relevant Implications for Application in the Steady State – 13

References – 14
Technical Aspects of Contrast Enhanced MRA – First Pass and Steady State

Harald H. Quick

2.1 Introduction – 18
2.2 Hardware – 18
  2.2.1 Main Magnet – 18
  2.2.2 Gradient System – 18
  2.2.3 RF System – 18
2.3 Data Acquisition: from k-Space to MRA Images – 20
  2.3.1 Parallel Imaging Strategies – 20
2.4 Data Acquisition and Contrast Kinetics – 23
  2.4.1 First pass MRA – 23
  2.4.2 Steady state MRA – 24
  2.4.3 Suppression of Venous Signal – 24
2.5 Extending the Field-of-View – 26
  2.5.1 Multi-station Peripheral MRA – 27
  2.5.2 Continuously Moving Table Peripheral MRA – 28
2.6 Conclusion – 30

References – 30
Risks and Safety Issues Related to Radiological Imaging, in Particular MRI

Gunnar Brix

3.1 Introduction  –  36
3.2 Risks Related to Imaging Procedures Using Ionizing Radiation  –  36
3.3 Risks Related to MRI Procedures  –  36
  3.3.1 Safety Regulations and Operating Modes  –  36
  3.3.2 Static Magnetic Fields  –  37
  3.3.3 Time-varying Magnetic Gradient Fields  –  37
  3.3.4 Radiofrequency Electromagnetic Fields  –  38
  3.3.5 Special Safety Issues and Contraindications  –  40

References  –  40
Summary of Safety of Vasovist® at 0.03 mmol/kg Body Weight Dose – Clinical Data

Matthias Voth and Andrea Löwe

4.1 Introduction – 44
4.2 Vasovist® – 45
4.2.1 Clinical studies – 45
4.2.2 Recommended clinical dose (0.03 mmol Gd/kg) – 46
4.2.3 Safety in postmarketing surveillance – 48
4.2.4 Special populations – 48
4.2.5 Discussion – 48

References – 49
# Efficacy of Vasovist®: Overview of the Clinical Development Program

Mathias Goyen

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1</td>
<td>Introduction</td>
<td>52</td>
</tr>
<tr>
<td>5.2</td>
<td>Phase II Dose-Finding Studies</td>
<td>53</td>
</tr>
<tr>
<td>5.3</td>
<td>Phase III Trials</td>
<td>53</td>
</tr>
<tr>
<td>5.3.1</td>
<td>Iliac Arteries</td>
<td>54</td>
</tr>
<tr>
<td>5.3.2</td>
<td>Leg Arteries</td>
<td>54</td>
</tr>
<tr>
<td>5.3.3</td>
<td>Renal Arteries</td>
<td>54</td>
</tr>
<tr>
<td>5.3.4</td>
<td>Foot Arteries</td>
<td>54</td>
</tr>
<tr>
<td>5.3.5</td>
<td>Stenosis Quantification</td>
<td>56</td>
</tr>
<tr>
<td>5.4</td>
<td>Efficacy of Vasovist® at Low Albumin Levels</td>
<td>56</td>
</tr>
</tbody>
</table>

References | 56
Head and Neck MRA

Marco Essig and Frederik Giesel

6.1 Introduction – 60
6.2 Traditional MRA Techniques for Imaging the Head and Neck Vasculature: TOF and PC MRA – 61
6.3 CE-MRA: Benefit over non-contrast techniques – 61
6.4 Technical Challenges Facing CE-MRA – 61
6.5 Accuracy of Contrast-enhanced MRA in the Assessment of the Supra-aortic Vasculature – 61
6.6 Protocols for Supra-aortic Vessel Visualization – 62
6.7 Benefits of the Blood pool MR Contrast Agent Vasovist® – 62
6.8 Conclusions – 63

References – 67
Pulmonary MRA

Christian Fink, Ulrike Attenberger, and Konstantin Nikolaou

7.1 Introduction – 70

7.2 Technical Considerations – 70
  7.2.1 General Considerations – 70
  7.2.2 Introduction of Intravascular Contrast Agents – 70
  7.2.3 Perfusion MRI of the Lungs: Qualitative and Quantitative Approach – 71
  7.2.4 Imaging the Pulmonary Vasculature at 3 Tesla – 73

7.3 Clinical Applications – 73
  7.3.1 Pulmonary MRA in Acute Pulmonary Embolism – 74
  7.3.2 Venous Imaging – 74
  7.3.3 Imaging of Patients with Pulmonary Arterial Hypertension – 75

7.4 Conclusions – 76

References – 77
Abdominal MRA

Henrik J. Michaely

8.1 Introduction – 82
8.2 Technical Considerations for Imaging with Vasovist* – 82
8.3 Contrast Agent Administration – 83
8.4 Clinical Indications – 84
8.5 New Diagnostic Possibilities – 89
References – 91
MRA of the Peripheral Vasculature

Tim Leiner and Jeffrey H. Maki

9.1 Introduction – 94
9.2 Technical Considerations and Imaging Protocols – 94
  9.2.1 Vasovist® Versus Conventional Contrast Media – 94
  9.2.2 Considerations with Regard to Vasovist*-enhanced Peripheral MRA Imaging Protocols – 95
  9.2.3 Vasovist® Injection Protocol – 96
9.3 Clinical Indications – 96
  9.3.1 Upper Extremities – 96
  9.3.2 Lower Extremity CE-MRA – 102
9.4 Diagnostic Accuracy of MRA for Evaluation of Peripheral Arterial Occlusive Disease – 112
9.5 Vasovist*-enhanced Imaging – 112
9.6 Conclusions – 112
Whole-body MRA

Harald Kramer, Maximilian F. Reiser, and Konstantin Nikolaou

11.1 Introduction – 132
11.2 Clinical Rationale – 132
11.3 Whole-body MRA – 134
11.4 Whole-body MRA Protocols – 135
11.5 Whole-body MRA with Intravascular Contrast Agents – 136
11.6 Clinical Applications – 136
  11.6.1 Whole-body MRA as a Replacement for Run-off Studies – 137
  11.6.2 Thromboembolic Diseases – 137
  11.6.3 Screening for Atherosclerotic Disease – 137

References – 138
Endoleak Imaging

Sandra A.P. Cornelissen, Mathias Prokop, Hence J.M. Verhagen, and Lambertus W. Bartels

12.1 Introduction   - 140
12.2 Non-shrinking Aneurysms   - 140
12.2.1 Endoleaks   - 140
12.2.2 The Endotension Problem   - 140
12.3 Challenges of Imaging Follow-up after EVAR   - 141
12.3.1 CT and CTA   - 141
12.3.2 MR and MRA   - 142
12.4 A new Approach to Endoleak Imaging: Vasovist®-enhanced MRA   - 143
12.4.1 General principle   - 143
12.4.2 Examination Technique   - 143
12.4.3 Vasovist® for Detection of Slow-flow Endoleak   - 143
12.5 Summary   - 146

References   - 146
Gastrointestinal Bleeding

Joachim Lotz

13.1 Introduction – 148
13.2 Diagnostic Challenge of GI Bleeding – 148
13.3 Upper GI Tract – 149
13.4 Lower GI Tract – 149
13.5 Small Intestine – 150
13.6 GI Bleeding and MRI – 153
13.7 Blood pool Contrast Agents – 153
13.8 Summary – 154

References – 155
Vasovist® for Imaging Ischemic and Congenital Heart Disease

Sebastian Kelle, Gerald Greil, Reza Razavi, and Eike Nagel

14.1 Introduction – 160
14.2 Magnetic Resonance Coronary Angiography (MRCA) – 160
14.3 Visualization of the Cardiac Venous System Using Vasovist® – 161
14.4 Detection of Myocardial Perfusion Defects with Vasovist® – 162
14.5 Late Gadolinium Enhancement – 163
14.6 Use of Vasovist® in Congenital Heart Disease – 164
14.7 Conclusion – 166

References – 167
Vasovist® in Brain Tumor Imaging

Marco Essig and Clemens Fitzek

15.1 Introduction – 170
15.2 First Experience with Vasovist® in Human Brain Tumor Imaging – 171
15.3 Practical Aspects – 178

References – 178
Vasovist® for Breast Cancer Recognition

Joan C. Vilanova and Klaus Wasser

17.1 Introduction  – 194
17.2 Vasovist® for Breast MRI – 194
17.3 Additional Benefits – 194
17.4 Conclusion – 197

References – 197
Vasovist® for Multiple Sclerosis Recognition

Michael Forsting

18.1 Introduction  – 200
18.2 Diagnostic Criteria  – 200
18.3 Radiological Examinations  – 201
18.4 Classical Findings in MRI  – 201
18.5 Recommendations with Regard to MR Technique  – 202
18.6 Role of Contrast Agents  – 203
18.7 Variants of MS  – 204
18.8 Differential Diagnosis  – 204
18.9 Conclusion  – 205
References  – 205
Interventional MR Imaging

Michael Bock and Frank Wacker

19.1 Introduction – 208

19.2 Technical Prerequisites – 208
19.2.1 Vertical C-arm Magnets – 208
19.2.2 Horizontal Solenoid Magnets – 209
19.2.3 XMR Systems – 209
19.2.4 Accessories – 210

19.3 Device Tracking – 210
19.3.1 Passive Markers – 210
19.3.2 Direct Currents – 211
19.3.3 Inductively Coupled Resonance Circuits – 211
19.3.4 Tracking and Profiling RF Coils – 212
19.3.5 Gradient Field Measurement – 212

19.4 Pulse Sequences for Interventional MRI – 213
19.4.1 Fast Low-Angle Shot (FLASH) – 213
19.4.2 Balanced Steady state-Free Precession – 214
19.4.3 Other Fast Sequences for Real-Time Imaging – 214

19.5 Clinical Applications – 215
19.5.1 Intravascular Interventions – 215
19.5.2 Percutaneous Procedures – 215

19.6 Summary – 217

References – 217
Vasovist® in Lymphography

Christoph U. Herborn

20.1 Introduction - 220
20.2 Lymphatic Anatomy and Physiology - 220
20.3 Lymph Nodes - 220
20.4 Methods of Contrast Agent Administration for Lymph Node Imaging - 220
20.5 Imaging Lymph Nodes - 221
20.6 Unenhanced MRI of the Lymphatic System - 221
20.7 Indirect Intravenous MR Lymphography - 221
20.8 Indirect Interstitial MR Lymphography - 222
20.9 Conclusion - 224

References - 224
Image Post-processing of Blood Pool MR Angiograms

Joachim Graessner

21.1 Introduction  – 228
21.2 Image Post-processing Techniques  – 229
  21.2.1 Introduction  – 229
  21.2.2 Subtraction  – 229
  21.2.3 MIP and Thin MIP  – 230
  21.2.4 MPR and Thick MPR  – 231
  21.2.5 SSD, VRT, Thin VRT, and 4D Viewing  – 231
  21.2.6 Quantitative Analysis, Vesselview  – 234
  21.2.7 A-V Separation  – 234
  21.2.8 Virtual Intraluminal Endoscopy (Fly Through)  – 234
  21.2.9 Composing  – 236
  21.2.10 Fusion of Image Series  – 236
21.3 Summary  – 237

References  – 238
Health Economic Benefits of Vasovist®

Carsten Schwenke, Susanne Kienbaum, and Karsten Bergmann

22.1 Introduction – 242

22.2 Objective of the Health Economic Evaluation for Vasovist*-MRA – 242

22.3 Health Economic Evaluation: Technical Abilities – 243
    22.3.1 Health Economic Evaluation: Clinical Development – 243
    22.3.2 Health Economic Evaluation: Real-world Experience – 244

22.4 Health Economic Modeling – 245
    22.4.1 Methods – 245
    22.4.2 Results: Cost-effectiveness Calculations – 247

22.5 Conclusions – 248

References – 249
Patient Management and Referrals:
The Impact of High-resolution Steady state MRA with Vasovist®

Winfried A. Willinek, Dariusch R. Hadizadeh

23.1 Introduction — 252
23.2 Technical Considerations — 252
23.3 Peripheral Arterial Disease Detection and Treatment — 252
23.4 Rationale for High-resolution MRA in the Steady State — 253
23.5 Patient Management and Clinical Cases — 253
23.6 Referrers — 256

References — 257